Elin Svensson

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Koele, Simon E.; Stoycheva, Krista; Mtweve, Cyprian; Manyama, Christina et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2305-2313, 2025

• DOI för Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
• Ladda ner fulltext (pdf) av Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

Wijk, Marie; Wasmann, Roeland E.; Jacobson, Karen R.; Svensson, Elin M. et al.

Ingår i CPT, s. 1042-1049, 2025

• DOI för A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling
• Ladda ner fulltext (pdf) av A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Karlsson, Mats O. et al.

Ingår i CPT, s. 1252-1261, 2025

• DOI för Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)
• Ladda ner fulltext (pdf) av Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Lin, Yu‐Jou; van der Laan, Louvina E.; Karlsson, Mats O.; Garcia‐Prats, Anthony J. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 1292-1302, 2025

• DOI för Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis
• Ladda ner fulltext (pdf) av Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

Palmer, Megan; Zou, Yuanxi; Hesseling, Anneke C.; van der Laan, Louvina et al.

Ingår i British Journal of Clinical Pharmacology, s. 1853-1864, 2025

• DOI för Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis
• Ladda ner fulltext (pdf) av Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

Koele, Simon E.; Stoycheva, Krista; Mtweve, Cyprian; Manyama, Christina et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2305-2313, 2025

• DOI för Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
• Ladda ner fulltext (pdf) av Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB

A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

Wijk, Marie; Wasmann, Roeland E.; Jacobson, Karen R.; Svensson, Elin M. et al.

Ingår i CPT, s. 1042-1049, 2025

• DOI för A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling
• Ladda ner fulltext (pdf) av A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Karlsson, Mats O. et al.

Ingår i CPT, s. 1252-1261, 2025

• DOI för Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)
• Ladda ner fulltext (pdf) av Establishing the Exposure-QT Relationship During Bedaquiline Treatment Using a Time-Varying Tuberculosis-Specific Correction Factor (QTcTBT)

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Lin, Yu‐Jou; van der Laan, Louvina E.; Karlsson, Mats O.; Garcia‐Prats, Anthony J. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 1292-1302, 2025

• DOI för Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis
• Ladda ner fulltext (pdf) av Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

Palmer, Megan; Zou, Yuanxi; Hesseling, Anneke C.; van der Laan, Louvina et al.

Ingår i British Journal of Clinical Pharmacology, s. 1853-1864, 2025

• DOI för Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis
• Ladda ner fulltext (pdf) av Population pharmacokinetics and dosing of dispersible moxifloxacin formulation in children with rifampicin‐resistant tuberculosis

In reply to the Letter to the Editor regarding 'Development and Validation of a Time-Varying Correction Factor for QT Interval Assessment in Drug-Resistant Tuberculosis Patients'

Vongjarudech, Thanakorn; Svensson, Elin

Ingår i International Journal of Antimicrobial Agents, 2025

• DOI för In reply to the Letter to the Editor regarding 'Development and Validation of a Time-Varying Correction Factor for QT Interval Assessment in Drug-Resistant Tuberculosis Patients'

Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043

Koele, Simon E.; Heinrich, Norbert; De Jager, Veronique R.; Dreisbach, Julia et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1315-1323, 2025

• DOI för Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043
• Ladda ner fulltext (pdf) av Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043

Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

Raaijmakers, J.; Salillas, S.; Aarnoutse, R.; Svensson, Elin M. et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2025

• DOI för Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system
• Ladda ner fulltext (pdf) av Bedaquiline does not enhance a clofazimine-azithromycin-ethambutol regimen against Mycobacterium avium in the hollow-fiber system

Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery

Wen, Haini; Sadiq, Muhammad Waqas; Friberg, Lena E.; Svensson, Elin M.

Ingår i CPT, s. 796-806, 2025

• DOI för Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery
• Ladda ner fulltext (pdf) av Translational Physiologically Based Pharmacokinetic Modeling to Predict Human Pulmonary Kinetics After Lung Delivery

Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas

Waalewijn, Hylke; Almett, Mounier; Wasmann, Roeland E.; Cressey, Tim R. et al.

Ingår i The Lancet Child and Adolescent Health, s. 274-282, 2025

• DOI för Simplifying medicine dosing for children by harmonising weight bands across therapeutic areas

The importance of getting the dose right in the treatment of tuberculosis

Dudnyk, Andrii; Lutchmun, Wandini; Duarte, Raquel; Lange, Christoph et al.

Ingår i Breathe, 2025

• DOI för The importance of getting the dose right in the treatment of tuberculosis
• Ladda ner fulltext (pdf) av The importance of getting the dose right in the treatment of tuberculosis

Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Vongjarudech, Thanakorn; Dosne, Anne-Gaelle; Remmerie, Bart; Dooley, Kelly E. et al.

Ingår i International Journal of Antimicrobial Agents, 2025

• DOI för Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients
• Ladda ner fulltext (pdf) av Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients

Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system

Raaijmakers, Jelmer; Ruth, Mike M.; Schildkraut, Jodie A.; van den Hombergh, Erik et al.

Ingår i International Journal of Antimicrobial Agents, 2025

• DOI för Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system
• Ladda ner fulltext (pdf) av Replacing rifampicin with minocycline increases the activity of the treatment regimen for Mycobacterium avium complex pulmonary disease in a dynamic hollow-fibre system

Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification

Dufault, Suzanne M.; Davies, Geraint R.; Svensson, Elin M.; Sloan, Derek J. et al.

Ingår i International Journal of Antimicrobial Agents, 2025

• DOI för Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification
• Ladda ner fulltext (pdf) av Analysis of time-to-positivity data in tuberculosis treatment studies: Identifying a new limit of quantification

A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Lin, Yu-Jou; Zou, Yuanxi; Karlsson, Mats O.; Svensson, Elin

Ingår i Journal of Antimicrobial Chemotherapy, s. 2561-2569, 2024

• DOI för A pharmacometric multistate model for predicting long-term treatment outcomes of patients with pulmonary TB

Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV

Montepiedra, Grace; Svensson, Elin; Wong, Weng Kee; Hooker, Andrew

Ingår i CPT, s. 270-280, 2024

• DOI för Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV
• Ladda ner fulltext (pdf) av Optimizing the design of a pharmacokinetic trial to evaluate the dosing scheme of a novel tuberculosis drug in children living with or without HIV

A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease

Stemkens, Ralf; Lemson, Arthur; Koele, Simon E.; Svensson, Elin M. et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3100-3108, 2024

• DOI för A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease
• Ladda ner fulltext (pdf) av A loading dose of clofazimine to rapidly achieve steady-state-like concentrations in patients with nontuberculous mycobacterial disease

Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Walter, Kerstin; te Brake, Lindsey H. M.; Lemm, Ann-Kathrin; Hoelscher, Michael et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 2607-2610, 2024

• DOI för Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures
• Ladda ner fulltext (pdf) av Investigating the treatment shortening potential of a combination of bedaquiline, delamanid and moxifloxacin with and without sutezolid, in a murine tuberculosis model with confirmed drug exposures

Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model

Salillas, Sandra; Raaijmakers, Jelmer; Aarnoutse, Rob E.; Svensson, Elin et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2024

• DOI för Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model
• Ladda ner fulltext (pdf) av Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model

Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling

Koele, Simon E; Dorlo, Thomas P. C.; Upton, Caryn M; Aarnoutse, Rob E et al.

Ingår i CPT, s. 374-385, 2024

• DOI för Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling
• Ladda ner fulltext (pdf) av Power to identify exposure-response relationships in phase IIa pulmonary tuberculosis trials with multi-dimensional bacterial load modeling

Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?

Nardotto, Glauco Henrique Balthazar; Svensson, Elin; Bollela, Valdes Roberto; Rocha, Adriana et al.

Ingår i Pharmaceutics, 2024

• DOI för Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?
• Ladda ner fulltext (pdf) av Effect of Interindividual Variability in Metabolic Clearance and Relative Bioavailability on Rifampicin Exposure in Tuberculosis Patients with and without HIV Co-Infection: Does Formulation Quality Matter?

Conjugated hyperbilirubinemia associated with accidental rifapentine overdose

Yohane, M.; Naufal, F.; Endoza-Ticona, A. M.; Svensson, Elin M. et al.

Ingår i The International Journal of Tuberculosis and Lung Disease, s. 354-356, 2024

• DOI för Conjugated hyperbilirubinemia associated with accidental rifapentine overdose

Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers

Zou, Yuanxi; de Jager, Veronique; Hesseling, Anneke C.; Diacon, Andreas H. et al.

Ingår i British Journal of Clinical Pharmacology, 2023

• DOI för Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers
• Ladda ner fulltext (pdf) av Relative bioavailability of delamanid 50 mg tablets dispersed in water in healthy adult volunteers

Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

Prins, H. A. B.; Zino, L.; Svensson, Elin M.; Verbon, A. et al.

Ingår i International Journal of Antimicrobial Agents, 2023

• DOI för Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)
• Ladda ner fulltext (pdf) av Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA)

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

Dierig, A.; Hoelscher, M.; Schultz, S.; Hoffmann, L. et al.

Ingår i Trials, 2023

• DOI för A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis
• Ladda ner fulltext (pdf) av A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis

Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Susanto, Budi O.; Svensson, Elin M.; te Brake, Lindsey; Aarnoutse, Rob E. et al.

Ingår i International Journal of Antimicrobial Agents, 2023

• DOI för Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin
• Ladda ner fulltext (pdf) av Model-based analysis of bactericidal activity and a new dosing strategy for optimised-dose rifampicin

Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis

Litjens, Carlijn H. C.; Verscheijden, Laurens F. M.; Svensson, Elin M.; van den Broek, Petra H. H. et al.

Ingår i Antibiotics, 2023

• DOI för Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis
• Ladda ner fulltext (pdf) av Physiologically-Based Pharmacokinetic Modelling to Predict the Pharmacokinetics and Pharmacodynamics of Linezolid in Adults and Children with Tuberculous Meningitis

Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Ayoun Alsoud, Rami; Svensson, Robin J.; Svensson, Elin; Gillespie, Stephen H. H. et al.

Ingår i Frontiers in Pharmacology, 2023

• DOI för Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development
• Ladda ner fulltext (pdf) av Combined quantitative tuberculosis biomarker model for time-to-positivity and colony forming unit to support tuberculosis drug development

Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Stemkens, Ralf; de Jager, Veronique; Dawson, Rodney; Diacon, Andreas H. et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2023

• DOI för Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis
• Ladda ner fulltext (pdf) av Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosis

Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Garcia-Prats, Anthony J.; Hoddinott, Graeme; Howell, Pauline; Hughes, Jennifer et al.

Ingår i The Lancet - Infectious diseases, s. 778-780, 2023

• DOI för Children deserve simple, short, safe, and effective treatment for rifampicin-resistant tuberculosis

Clinical standards for the management of adverse effects during treatment for TB

Singh, K. P.; Carvalho, A. C. C.; Centis, R.; D'Ambrosio, L. et al.

Ingår i The International Journal of Tuberculosis and Lung Disease, s. 506-519, 2023

• DOI för Clinical standards for the management of adverse effects during treatment for TB
• Ladda ner fulltext (pdf) av Clinical standards for the management of adverse effects during treatment for TB

Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Zou, Yuanxi; Nedelman, Jerry; Lombardi, Antonio; Pappas, Frances et al.

Ingår i Clinical Pharmacokinetics, s. 1585-1593, 2022

• DOI för Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling
• Ladda ner fulltext (pdf) av Characterizing Absorption Properties of Dispersible Pretomanid Tablets Using Population Pharmacokinetic Modelling

Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments

Bukkems, V. E.; van Hove, H.; Roelofsen, D.; Freriksen, J. J. M. et al.

Ingår i Clinical Pharmacokinetics, s. 1129-1141, 2022

• DOI för Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments
• Ladda ner fulltext (pdf) av Prediction of Maternal and Fetal Doravirine Exposure by Integrating Physiologically Based Pharmacokinetic Modeling and Human Placenta Perfusion Experiments

Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment

van Beek, Stijn W.; Tanneau, Lénaïg; Meintjes, Graeme; Wasserman, Sean et al.

Ingår i OPEN FORUM INFECTIOUS DISEASES, 2022

• DOI för Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment
• Ladda ner fulltext (pdf) av Model-Predicted Impact of ECG Monitoring Strategies During Bedaquiline Treatment

Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Denti, Paolo; Wasmann, Roeland E.; van Rie, Annelies; Winckler, Jana et al.

Ingår i Clinical Infectious Diseases, s. 141-151, 2022

• DOI för Optimizing Dosing and Fixed-Dose Combinations of Rifampicin, Isoniazid, and Pyrazinamide in Pediatric Patients With Tuberculosis: A Prospective Population Pharmacokinetic Study

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Keutzer, Lina; You, Huifang; Farnoud, Ali; Nyberg, Joakim et al.

Ingår i Pharmaceutics, 2022

• DOI för Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin
• Ladda ner fulltext (pdf) av Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

Tanneau, Lénaïg; Karlsson, Mats; Diacon, Andreas H; Shenje, Justin et al.

Ingår i Clinical Pharmacokinetics, s. 1177-1185, 2022

• DOI för Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline
• Ladda ner fulltext (pdf) av Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline

Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

De Jager, Veronique; Gupte, Nikhil; Nunes, Silvia; Barnes, Grace L. et al.

Ingår i American Journal of Respiratory and Critical Care Medicine, s. 1228-1235, 2022

• DOI för Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

Pharmacometrics - tools to assure optimal medicine use in low- and middle-income countries: Editorial

Abulfathi, Ahmed A.; Chaba, Linda A.; Svensson, Elin; Pillai, Goonaseelan C. et al.

Ingår i Frontiers in Pharmacology, 2022

• DOI för Pharmacometrics - tools to assure optimal medicine use in low- and middle-income countries: Editorial
• Ladda ner fulltext (pdf) av Pharmacometrics - tools to assure optimal medicine use in low- and middle-income countries: Editorial

Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Ruth, Mike Marvin; Raaijmakers, Jelmer; van den Hombergh, Erik; Aarnoutse, Rob et al.

Ingår i Clinical Microbiology and Infection, s. 4480-4480000000, 2022

• DOI för Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics
• Ladda ner fulltext (pdf) av Standard therapy of Mycobacterium avium complex pulmonary disease shows limited efficacy in an open source hollow fibre system that simulates human plasma and epithelial lining fluid pharmacokinetics

Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease

Danho, Rabi; Schildkraut, Jodie A.; Zweijpfenning, Sanne M. H.; Svensson, Elin et al.

Ingår i Chest, s. 370-372, 2022

• DOI för Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease
• Ladda ner fulltext (pdf) av Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease

Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment

Koele, Simon E.; van Beek, Stijn W.; Maartens, Gary; Brust, James C. M. et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2022

• DOI för Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment

Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Sasaki, Tomohiro; Svensson, Elin; Wang, Xiaofeng; Wang, Yanlin et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2022

• DOI för Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis
• Ladda ner fulltext (pdf) av Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis

Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Litjens, Carlijn H. C.; Verscheijden, Laurens F. M.; Bolwerk, Celine; Greupink, Rick et al.

Ingår i Journal of clinical pharmacology, s. 385-396, 2022

• DOI för Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling
• Ladda ner fulltext (pdf) av Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling

Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Tanneau, Lénaïg; Karlsson, Mats; Rosenkranz, Susan L.; Cramer, Yoninah S. et al.

Ingår i Clinical Pharmacology and Therapeutics, s. 873-881, 2022

• DOI för Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens
• Ladda ner fulltext (pdf) av Assessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens

Pharmacometrics in tuberculosis: progress and opportunities

Wilkins, Justin J.; Svensson, Elin; Ernest, Jacqueline P.; Savic, Radojka M. et al.

Ingår i International Journal of Antimicrobial Agents, 2022

• DOI för Pharmacometrics in tuberculosis: progress and opportunities
• Ladda ner fulltext (pdf) av Pharmacometrics in tuberculosis: progress and opportunities

Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

Waalewijn, Hylke; Stol, Kim; van der Knaap, Linda; Fraaij, Pieter L. A. et al.

Ingår i AIDS, s. 2077-2079, 2022

• DOI för Adequate exposure of 50 mg dolutegravir in children weighing 20 to 40 kg outside of sub-Sahara Africa

Drug concentration at the site of disease in children with pulmonary tuberculosis

Lopez-Varela, Elisa; Abulfathi, Ahmed A.; Strydom, Natasha; Goussard, Pierre et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1710-1719, 2022

• DOI för Drug concentration at the site of disease in children with pulmonary tuberculosis
• Ladda ner fulltext (pdf) av Drug concentration at the site of disease in children with pulmonary tuberculosis

Clinical standards for the dosing and management of TB drugs

Alffenaar, J. W. C.; Stocker, S. L.; Forsman, L. Davies; Garcia-Prats, A. et al.

Ingår i The International Journal of Tuberculosis and Lung Disease, s. 483-+, 2022

• DOI för Clinical standards for the dosing and management of TB drugs

Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

Haas, David W.; Abdelwahab, Mahmoud Tareq; van Beek, Stijn W.; Baker, Paxton et al.

Ingår i Journal of Infectious Diseases, s. 147-156, 2022

• DOI för Pharmacogenetics of Between-Individual Variability in Plasma Clearance of Bedaquiline and Clofazimine in South Africa

Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

de Rouw, Nikki; Boosman, Rene J.; Huitema, Alwin D. R.; Hilbrands, Luuk B. et al.

Ingår i Clinical Pharmacokinetics, s. 649-654, 2021

• DOI för Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis
• Ladda ner fulltext (pdf) av Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis

Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa

van Beek, Stijn W.; Svensson, Elin; Tiono, Alfred B.; Okebe, Joseph et al.

Ingår i Parasites & Vectors, 2021

• DOI för Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa
• Ladda ner fulltext (pdf) av Model-based assessment of the safety of community interventions with primaquine in sub-Saharan Africa

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis

Abulfathi, Ahmed A.; de Jager, Veronique; van Brakel, Elana; Reuter, Helmuth et al.

Ingår i Frontiers in Pharmacology, 2021

• DOI för The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
• Ladda ner fulltext (pdf) av The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis

Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Tanneau, Lénaïg; Svensson, Elin; Rossenu, Stefaan; Karlsson, Mats

Ingår i CPT, s. 1538-1549, 2021

• DOI för Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis
• Ladda ner fulltext (pdf) av Exposure–safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug‐resistant tuberculosis

Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Ngwalero, Precious; Brust, James C. M.; van Beek, Stijn W.; Wasserman, Sean et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2021

• DOI för Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis
• Ladda ner fulltext (pdf) av Relationship between Plasma and Intracellular Concentrations of Bedaquiline and Its M2 Metabolite in South African Patients with Rifampin-Resistant Tuberculosis

Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis

Abdelwahab, Mahmoud Tareq; Court, Richard; Everitt, Daniel; Diacon, Andreas H. et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2021

• DOI för Effect of Clofazimine Concentration on QT Prolongation in Patients Treated for Tuberculosis

Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model

Pieterman, E. D.; van den Berg, S.; van der Meijden, A.; Svensson, Elin et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2021

• DOI för Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model

An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies

Sonawane, Vidhisha V.; Ruth, Mike M.; Pennings, Lian J.; Svensson, Elin et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2021

• DOI för An In Vitro Perspective on What Individual Antimicrobials Add to Mycobacterium avium Complex Therapies

High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial

Cresswell, Fiona; Meya, David B.; Kagimu, Enock; Grint, Daniel et al.

Ingår i Clinical Infectious Diseases, s. 876-884, 2021

• DOI för High-Dose Oral and Intravenous Rifampicin for the Treatment of Tuberculous Meningitis in Predominantly Human Immunodeficiency Virus (HIV)-Positive Ugandan Adults: A Phase II Open-Label Randomized Controlled Trial

Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Garcia-Prats, Anthony J.; Svensson, Elin; Winckler, Jana; Draper, Heather R. et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3237-3246, 2021

• DOI för Pharmacokinetics and safety of high-dose rifampicin in children with TB: the Opti-Rif trial

Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children

Wasmann, Roeland E.; Svensson, Elin; Walker, A. Sarah; Clements, Michelle N. et al.

Ingår i British Journal of Clinical Pharmacology, s. 2847-2854, 2021

• DOI för Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children
• Ladda ner fulltext (pdf) av Constructing a representative in-silico population for paediatric simulations: Application to HIV-positive African children

Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies

Wasmann, Roeland E.; Svensson, Elin; Schalkwijk, Stein J.; Brüggemann, Roger J. et al.

Ingår i European Journal of Clinical Pharmacology, s. 727-733, 2021

• DOI för Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies
• Ladda ner fulltext (pdf) av Normal fat mass cannot be reliably estimated in typical pharmacokinetic studies

Pharmacometrics meets statistics-A synergy for modern drug development

Ryeznik, Yevgen; Sverdlov, Oleksandr; Svensson, Elin; Montepiedra, Grace et al.

Ingår i CPT, s. 1134-1149, 2021

• DOI för Pharmacometrics meets statistics-A synergy for modern drug development
• Ladda ner fulltext (pdf) av Pharmacometrics meets statistics-A synergy for modern drug development

Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin

te Brake, Lindsey H. M.; de Jager, Veronique; Narunsky, Kim; Vanker, Naadira et al.

Ingår i European Respiratory Journal, 2021

• DOI för Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin
• Ladda ner fulltext (pdf) av Increased bactericidal activity but dose-limiting intolerability at 50 mg.kg(-1) rifampicin

A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV

Bukkems, Vera E.; Post, Teun M.; Colbers, Angela P.; Burger, David M. et al.

Ingår i CPT, s. 161-172, 2021

• DOI för A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV
• Ladda ner fulltext (pdf) av A population pharmacokinetics analysis assessing the exposure of raltegravir once-daily 1200 mg in pregnant women living with HIV

A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

van Beek, Stijn W.; ter Heine, Rob; Alffenaar, Jan-Willem C.; Magis-Escurra, Cecile et al.

Ingår i Clinical Pharmacokinetics, s. 943-953, 2021

• DOI för A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis
• Ladda ner fulltext (pdf) av A Model-Informed Method for the Purpose of Precision Dosing of Isoniazid in Pulmonary Tuberculosis

Rifampicin can be given as flat-dosing instead of weight-band dosing

Susanto, Budi Octasari; Svensson, Robin J.; Svensson, Elin M.; Aarnoutse, Rob et al.

Ingår i Clinical Infectious Diseases, s. 3055-3060, 2020

• DOI för Rifampicin can be given as flat-dosing instead of weight-band dosing
• Ladda ner fulltext (pdf) av Rifampicin can be given as flat-dosing instead of weight-band dosing

Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis

Tanneau, Lénaïg; Karlsson, Mats O.; Svensson, Elin

Ingår i British Journal of Clinical Pharmacology, s. 913-922, 2020

• DOI för Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis
• Ladda ner fulltext (pdf) av Understanding the drug exposure-response relationship of bedaquiline to predict efficacy for novel dosing regimens in the treatment of multidrug-resistant tuberculosis

Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens

Abulfathi, Ahmed A.; Assawasuwannakit, Piyanan; Donald, Peter R.; Diacon, Andreas H. et al.

Ingår i European Journal of Clinical Pharmacology, s. 1557-1565, 2020

• DOI för Probability of mycobactericidal activity of para-aminosalicylic acid with novel dosing regimens

Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials

Svensson, Elin M.; Dian, Sofiati; te Brake, Lindsey; Ganiem, Ahmad Rizal et al.

Ingår i Clinical Infectious Diseases, s. 1817-1823, 2020

• DOI för Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials
• Ladda ner fulltext (pdf) av Model-based meta-analysis of rifampicin exposure and mortality in Indonesian tuberculous meningitis trials

Clofazimine pharmacokinetics in patients with TB: dosing implications

Abdelwahab, Mahmoud Tareq; Wasserman, Sean; Brust, James C. M.; Gandhi, Neel R. et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3269-3277, 2020

• DOI för Clofazimine pharmacokinetics in patients with TB: dosing implications

Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Ruth, Mike Marvin; Koeken, Valerie A. C. M.; Pennings, Lian J.; Svensson, Elin et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 609-617, 2020

• DOI för Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?
• Ladda ner fulltext (pdf) av Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?

Protein binding of rifampicin is not saturated when using high-dose rifampicin

Litjens, Carlijn H. C.; Aarnoutse, Rob E.; Kolmer, Eleonora W. J. van Ewijk-Beneken; Svensson, Elin et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 986-990, 2019

• DOI för Protein binding of rifampicin is not saturated when using high-dose rifampicin

Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus

Ruth, Mike Marvin; van Rossum, Mara; Koeken, Valerie A. C. M.; Pennings, Lian J. et al.

Ingår i Antimicrobial Agents and Chemotherapy, 2019

• DOI för Auranofin Activity Exposes Thioredoxin Reductase as a Viable Drug Target in Mycobacterium abscessus

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

van Beek, Stijn W.; ter Heine, Rob; Keizer, Ron J.; Magis-Escurra, Cecile et al.

Ingår i Clinical Pharmacokinetics, s. 815-826, 2019

• DOI för Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin
• Ladda ner fulltext (pdf) av Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria

Ruth, Mike Marvin; Sangen, Jasper J. N.; Remmers, Karlijn; Pennings, Lian J. et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 935-943, 2019

• DOI för A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

Svensson, Elin; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Ingår i Clinical Pharmacokinetics, s. 591-599, 2018

• DOI för Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy
• Ladda ner fulltext (pdf) av Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy

The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Svensson, Elin M.; Svensson, Robin J.; te Brake, Lindsey H. M.; Boeree, Martin J. et al.

Ingår i Clinical Infectious Diseases, s. 34-41, 2018

• DOI för The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis
• Ladda ner fulltext (pdf) av The Potential for Treatment Shortening With Higher Rifampicin Doses: Relating Drug Exposure to Treatment Response in Patients With Pulmonary Tuberculosis

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

Svensson, Robin J.; Svensson, Elin; Aarnoutse, Rob E.; Diacon, Andreas H. et al.

Ingår i Journal of Infectious Diseases, s. 991-999, 2018

• DOI för Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations

Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children

Svensson, Elin; du Bois, Jeannine; Kitshoff, Rene; de Jager, Veronique R. et al.

Ingår i British Journal of Clinical Pharmacology, s. 2384-2392, 2018

• DOI för Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children
• Ladda ner fulltext (pdf) av Relative bioavailability of bedaquiline tablets suspended in water: Implications for dosing in children

Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Svensson, Elin M.; Yngman, Gunnar; Denti, Paolo; McIlleron, Helen et al.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, 2017

• DOI för Evidence-based design of fixed-dose combinations: principles and application to pediatric anti-tuberculosis therapy

Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Brill, Margreke JE; Svensson, Elin M; Pandie, Mishal; Maartens, Gary et al.

Ingår i International Journal of Antimicrobial Agents, s. 212-217, 2017

• DOI för Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis
• Ladda ner fulltext (pdf) av Confirming model-predicted pharmacokinetic interactions between bedaquiline and lopinavir/ritonavir or nevirapine in patients with HIV and drug resistant tuberculosis

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Svensson, Elin M.; Karlsson, Mats O

Ingår i Journal of Antimicrobial Chemotherapy, s. 3398-3405, 2017

• DOI för Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB
• Ladda ner fulltext (pdf) av Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB

Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Svensson, Elin M.; Acharya, Chayan; Clauson, Björn; Dooley, Kelly E. et al.

Ingår i AAPS Journal, s. 171-179, 2016

• DOI för Pharmacokinetic Interactions for Drugs with a Long Half-Life-Evidence for the Need of Model-Based Analysis

Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Hennig, Stefanie; Svensson, Elin M; Niebecker, Ronald; Fourie, P Bernard et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1330-1340, 2016

• DOI för Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs

Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Svensson, Elin M; Dosne, Anne-Gaëlle; Karlsson, Mats O

Ingår i CPT, s. 682-691, 2016

• DOI för Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin
• Ladda ner fulltext (pdf) av Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin

Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Svensson, Elin M.; Murray, Stephen; Karlsson, Mats O.; Dooley, Kelly E.

Ingår i Journal of Antimicrobial Chemotherapy, s. 1106-1114, 2015

• DOI för Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug

Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Svensson, Elin M.; Dooley, Kelly E.; Karlsson, Mats O.

Ingår i Antimicrobial Agents and Chemotherapy, s. 6406-6412, 2014

• DOI för Impact of Lopinavir-Ritonavir or Nevirapine on Bedaquiline Exposures and Potential Implications for Patients with Tuberculosis-HIV Coinfection

Use of a linearization approximation facilitating stochastic model building

Svensson, Elin M.; Karlsson, Mats O.

Ingår i Journal of Pharmacokinetics and Pharmacodynamics, s. 153-158, 2014

• DOI för Use of a linearization approximation facilitating stochastic model building
• Ladda ner fulltext (pdf) av Use of a linearization approximation facilitating stochastic model building

Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Svensson, Elin M.; Aweeka, Francesca; Park, Jeong-Gun; Marzan, Florence et al.

Ingår i Antimicrobial Agents and Chemotherapy, s. 2780-2787, 2013

• DOI för Model-Based Estimates of the Effects of Efavirenz on Bedaquiline Pharmacokinetics and Suggested Dose Adjustments for Patients Coinfected with HIV and Tuberculosis

Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Svensson, Elin; van der Walt, Jan-Stefan; Barnes, Karen I.; Cohen, Karen et al.

Ingår i British Journal of Clinical Pharmacology, s. 465-476, 2012

• DOI för Integration of data from multiple sources for simultaneous modelling analysis: experience from nevirapine population pharmacokinetics

Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

Gafar, Fajri; Wasmann, Roeland E.; McIlleron, Helen M.; Aarnoutse, Rob E. et al.

Ingår i European Respiratory Journal, 2023

• DOI för Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis
• Ladda ner fulltext (pdf) av Global estimates and determinants of antituberculosis drug pharmacokinetics in children and adolescents: a systematic review and individual patient data meta-analysis

Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects

Koele, Simon E.; Phillips, Patrick P. J.; Upton, Caryn M.; van Ingen, Jakko et al.

Ingår i International Journal of Antimicrobial Agents, 2023

• DOI för Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects
• Ladda ner fulltext (pdf) av Early bactericidal activity studies for pulmonary tuberculosis: A systematic review of methodological aspects

New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians

Diaz, Jessica M. Aguilar; Abulfathi, Ahmed A.; te Brake, Lindsey H. M.; van Ingen, Jakko et al.

Ingår i Respiration, s. 83-100, 2023

• DOI för New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians
• Ladda ner fulltext (pdf) av New and Repurposed Drugs for the Treatment of Active Tuberculosis: An Update for Clinicians

Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis

Radtke, Kendra K.; Svensson, Elin; van der Laan, Louvina E.; Hesseling, Anneke C. et al.

Ingår i Expert Review of Clinical Pharmacology, s. 161-174, 2022

• DOI för Emerging data on rifampicin pharmacokinetics and approaches to optimal dosing in children with tuberculosis

Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

Sturkenboom, Marieke G. G.; Martson, Anne-Grete; Svensson, Elin; Sloan, Derek J. et al.

Ingår i Clinical Pharmacokinetics, s. 685-710, 2021

• DOI för Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
• Ladda ner fulltext (pdf) av Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs

The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance

Abulfathi, Ahmed A.; Donald, Peter R.; Adams, Kim; Svensson, Elin et al.

Ingår i British Journal of Clinical Pharmacology, s. 2123-2132, 2020

• DOI för The pharmacokinetics of para-aminosalicylic acid and its relationship to efficacy and intolerance

Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

Jacobs, Tom G.; Svensson, Elin; Musiime, Victor; Rojo, Pablo et al.

Ingår i Journal of Antimicrobial Chemotherapy, s. 3433-3457, 2020

• DOI för Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review
• Ladda ner fulltext (pdf) av Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review

Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Abulfathi, Ahmed Aliyu; Decloedt, Eric H.; Svensson, Elin M.; Diacon, Andreas H. et al.

Ingår i Clinical Pharmacokinetics, s. 1103-1129, 2019

• DOI för Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis

Pharmacometric Models to Improve Treatment of Tuberculosis

Svensson, Elin M

2016

• Ladda ner fulltext (pdf) av Pharmacometric Models to Improve Treatment of Tuberculosis

Modeling of mycobacterial load reveals bedaquiline’s exposure-response relationship in patients with drug-resistant tuberculosis

Svensson, Elin M; Rossenu, Stefaan; Karlsson, Mats O

Pharmacodynamic interaction of bedaquiline and delamanid co-administration on QTcF interval prolongation

Tanneau, Lénaïg; Karlsson, Mats; Rosenkranz, Susan L; Cramer, Yoninah S et al.

A novel approach to evaluate the design of pediatric pharmacokinetic studies focused on accurate dose selection

Zou, Yuanxi; Nedelman, Jerry; Karlsson O, Mats; Svensson M, Elin